13th Five Year Plan: Business Opportunities and Challenges

<- 分享“上海美国商会”微信公众号到您的社交圈,让更多的人知道!

收藏文章 赞一个 已赞 2016-03-28 上海美国商会



China’s new 13th Five Year Plan signals a shift in Chinese government priorities away from unchecked economic development to a more human centered, environmentally sustainable development. What are the key parts of the plan and what will the impact be on foreign companies in China? AmCham Shanghai and USCBC have organized a presentation and panel discussion on the 13th Five Year Plan on Wednesday, April 6 from 11:30 to 13:30 at The Portman Ritz-Carlton Hotel. The event features a presentation by KPMG’s David Frey, who has had extensive meetings and discussions with the Chinese government on the plan. His presentation will be followed by a panel discussion from industry experts and leaders on the plan’s opportunities and challenges for companies in China. 


Agenda:

 

11:30     Registration and Lunch 

12:00     Kenneth Jarrett Welcome Remarks

12:05     USCBC Shanghai Representative Owen Haacke Comments

12:15     13th Five Year Plan Overview

               Presenters: David Frey, KPMG China Markets Strategy Partner

12:35      KPMG Q&A

12:45      Panel Discussion: 13th Five Year Plan Impact on Businesses

               Panelists: 

               Vijay Vaitheeswaran, The Economist Senior Correspondent 

               Eric Zwisler, Cardinal Health China Chairman

               Paulson Institute 

13:15     Q&A

13:30     Event Ends


About the Speakers and Panelists:


 David Frey is a Partner for Markets Strategy with KPMG in China. He advises multinational companies on strategic growth and expansion opportunities in China and across Asia Pacific. In addition, he leads KPMG’s US-China Strategic Corridor and has responsibility for the development of KPMG’s cross-border advisory profile. He appears regularly as a guest commentator in print media and on CNBC and CCTV regarding China’s economic development. David’s views are called upon by both foreign governments and the China government, having served as an expert witness at a US Congressional Commission hearing in Washington on China’s Five Year Plans, chairing a roundtable session at China’s prestigious Party School and hosting numerous sessions with the Development Research Center (DRC) of the State Council regarding the financing of China’s urbanization. Additionally he has been invited to participate in several closed-door sessions with Ambassadors posted in China, and frequently provides background briefings to company Boards meeting in China. 


Vijay V. Vaitheeswaran is an award-winning senior correspondent for The Economist. He joined the editorial staff in 1992 as its London-based Latin America correspondent, and later opened the magazine’s first bureau in Mexico City. From 1998 to 2006, he covered energy and the environment. From 2007 to 2011, his portfolio encompassed global health, pharmaceuticals and biotechnology. Vijay opened the newspaper’s first Shanghai bureau in 2012, and currently serves as the China Business Editor & Shanghai Bureau Chief. His latest book (published by Harper Collins) is “Need, Speed and Greed: How the New Rules of Innovation Can Transform Businesses, Propel Nations to Greatness, and Tame the World’s Most Wicked Problems.” Vijay is a life member of the Council on Foreign Relations and an advisor on sustainability and innovation to the World Economic Forum. 


Eric Zwisler is currently Chairman of Cardinal Health China, a subsidiary of Cardinal Health (CAH), a Fortune 20 company.  He’s been involved in healthcare businesses in Asia and particularly China for the last 26 years.  Prior to his current role, he was President of Cardinal Health China for three years. 

Eric has also served as CEO of Zuellig Pharma Asia Pacific, a privately owned industry leading Pan Asia healthcare distribution and services company with $8.5 billion turnover and 8,000 employees located in 15 Asian countries and regions. 


Earlier in his career he established and built a breakthrough healthcare distribution and services business in China for Zuellig Pharma. In his role as CEO of Zuellig Pharma Asia Pacific, Eric oversaw the sale of the China subsidiary to Cardinal Health in 2010 for $470 million.  Following the sale Eric returned to China to head-up the company he founded, now an integrated life sciences distribution and services company handling over $6 billion annually.  Eric is well versed in the acquisition and integration of Chinese companies having acquired over 12 Chinese-owned manufacturing, distribution, IT services and specialty retail pharmacy companies. 


If you have any question, please contact elyssa.gao@amcham-shanghai.org

Click "Read More" to RSVP.




【Follow Us 关注我们】

(Scan or long-press the QR code below or search "上海美国商会" in Official Accounts 扫描或长按二维码,或搜索公众号“上海美国商会”)

点击展开全文